| Name | Title | Contact Details |
|---|
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.
Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.
Virent Energy Systems is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.